BVSNMSHealthcare·Medical Devices#44 in industry

Bioventus Inc.

Reports in 8d· 2026-05-05

+26.4% · 90d

$10.01

-0.08 (-0.79%)

After-Hours $10.01(+0.00)

News

(2)

April 2026

Apr 22, 20265 days agoARSHealthcare

Bioventus outlines comprehensive legal and operational risk disclosures for investors

BVSBioventus Inc.

# 📜 What This Document Is This document is an Annual Report Supplement (Form ARS) that focuses heavily on Bioventus Inc.'s intellectual property (IP), trademarks, and the vast array of regulations that govern its operations. 🛡️ Because it is an ARS, it is a disclosure document designed to alert in

Read summaryView on SEC EDGAR

Apr 22, 20265 days agoDEF 14AHealthcare

BVS details proxy vote on electing directors and approving auditor

BVSBioventus Inc.

# 📜 What This Document Is 📜 This document is a definitive Proxy Statement (DEF 14A). 👉 Essentially, it is a mandatory annual report designed to inform the company's stockholders about the key decisions and issues that will be voted on at the Annual Meeting of Stockholders. * **Purpose:** The

Read summaryView on SEC EDGAR

Key Data

Market Cap$677.1M

Open$10.01

Prev Close$10.09

Day Range$9.71 – $10.24

52W Range$5.81 – $10.76

Volume313,680

P/E (TTM)30.33

EPS$0.33

Dividend Yield—

Beta0.69

Profit Margin4.00%

Revenue Growth2.80%

Price Target$14.80(+47.9%)

Next Earnings2026-05-05(8d)

Analyst Ratings

Strong Buy5 analysts

Buy 5Hold 0Sell 0

About

Bioventus Inc., a medical device company, focuses on relieving pain and addressing musculoskeletal therapies in the United States and internationally. The company's product portfolio includes pain treatments, which comprise various intra-articular and hyaluronic acid injections; peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis; and Stimrouter to treat chronic peripheral pain, and TalisMann provides stimulation to the targeted peripheral nerve, as well as XCELL PRP System, a benchtop device that processes whole blood to produce high-yield PRP with a 10-minute single-spin cycle. It also offers precision bone resection for patients with degenerative spine conditions and spinal deformities, as well as enables precision ultrasonic neuro and general surgery to address brain tumors and pathologies of the liver and other organs; and bone graft substitutes, including various products that facilitate optimal bone fusion. In addition, the company provides neXus, an ultrasonic surgical system; BoneScalpel, a surgical solution enabling precise cuts in hard tissue; BoneScalpel Access, for bone removal with visualization; SonaStar system, a precise ablation and removal of soft tissue; SonaStar Elite handpiece and accessories; SonicOne, an ultrasonic cleansing and debridement system; Osteoamp, an allograft-derived bone graft for orthopedic, neurosurgical, and reconstructive bone grafting procedures; Signafuse bone graft; Purebone, a natural osteoconductive scaffold; and Reficio demineralized bone matrix. The company's restorative therapies include minimally invasive fracture treatments and rehabilitation products. Its products also include Exogen, an ultrasound bone stimulation system. The company sells its products to healthcare institutions, physicians, patients, distributors and dealers. Bioventus Inc. was founded in 2011 and is headquartered in Durham, North Carolina.

Healthcare · Medical Devices

930 employees

www.bioventus.com